Navigation
Home
Advocating for Access
Background
Letters for Access
Press Releases For Access
Simplified Community Materials
Simplified Community Materials
Understanding your HCV infection
Community Led Reports
Country Information
Indonesia
India
Vietnam
Generic DAAs Pricing
Resources
Guidelines
Key Research Publication
Other Important Documents and Reports
News
Gallery
Photos
Video
Stories
Response from CEO, CHAI about the Quick Start program in November 2016
Response from CEO, CHAI about the Quick Start program in November 2016
Please click here
December 21, 2016
/
News
Share
the Post
Related
Posts
Availability and Pricing of Generic Sofosbuvir in India – Updated 10 September 2015
BMS’ patent bid for Hep C treatment Daclatasvir Challenged
Pricing of Indian generic sofosbuvir, 30th Jan,2016
The Updated Pricing of Ledipasvir and Sofosbuvir Co-formulated tablets
Progress report on access to hepatitis C treatment, WHO March 2018
Pricing and availability of generic Indian Ledipasvir and Sofosbuvir co-formulation as on 26 April 2016
Generic daclatasvir (60 mg) availability and India market pricing as of 30 January 2016
Updated Patent Situation on Key Products for Hepatitis C Treatment in Asia – August 2015
